Oral health management of patients at risk of medication-related osteonecrosis of the jaw

Source:
Scottish Dental Clinical Effectiveness Programme
Publisher:
Scottish Dental Clinical Effectiveness Programme (SDCEP)
Publication date:
30 March 2017

Abstract

There is an increased risk of oral health complications for patients prescribed anti-resorptive or anti-angiogenic drugs (medication-related osteonecrosis of the jaw, MRONJ). This guidance provides recommendations, advice and information to help dental practitioners manage the routine dental care of patients prescribed these drugs and is an update to the previous SDCEP Oral Health Management of Patients Prescribed Bisphosphonates.

The guidance is aimed primarily at dentists in primary care dental practice and will also be of relevance to the secondary care dental service, those involved in dental education and undergraduate trainees. The guidance is also of relevance to prescribers and dispensers of bisphosphonates and to patients.